biologic

Oziltus

denosumab-mobz

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameOziltus
Active ingredientdenosumab-mobz
Strength120MG/1.7ML (70MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.